Seattle Genetics Company Profile (NASDAQ:SGEN)

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

Seattle Genetics, Inc. (NASDAQ:SGEN) released its quarterly earnings results on Thursday, July, 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.03. The firm earned $108.20 million during the quarter, compared to the consensus estimate of $105.92 million. Seattle Genetics had a negative net margin of 47.38% and a negative return on equity of 32.87%. The company's revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.23) earnings per share. View Seattle Genetics' Earnings History.

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Seattle Genetics.

18 brokers have issued 1-year price targets for Seattle Genetics' shares. Their predictions range from $46.00 to $75.00. On average, they expect Seattle Genetics' share price to reach $61.25 in the next year. View Analyst Ratings for Seattle Genetics.

Here are some recent quotes from research analysts about Seattle Genetics stock:

• 1. Cann analysts commented, "Seattle Genetics announced today that preliminary clinical data for tisotumab vedotin from a Genmab-sponsored phase I/II clinical trial, GEN701, are being featured in an oral presentation at ESMO. Data were reported from an expansion cohort of the study including 34 patients with relapsed, recurrent and/or metastatic cervical cancer. It was reported that 32% of these patients achieved a response and 50% of patients achieved clinical benefit after 12 weeks. Median duration of confirmed responses was 8.3 months." (9/8/2017)
• 2. Cantor Fitzgerald analysts commented, "The Phase III ECHELON-1 study in previously untreated patients with advanced classical Hodgkin lymphoma met its primary endpoint of modified PFS (82.1% versus 77.2% at two years)." (6/26/2017)
• 3. Cowen and Company analysts commented, "SGEN announced this morning that following an interim safety look of 33A’s pivotal." (6/19/2017)
• 4. J P Morgan Chase & Co analysts commented, "With top-line results for ECHELON-1 (Adcetris in 1L Hodgkin lymphoma) reading out at some point in 2017, we conducted a detailed analysis of the trial design and available data and interviewed a couple more KOLs to help frame expectations. We are also updating our model to better account for doc feedback and re-treatment rates among the various approved Adcetris settings. The bottom line is that we are bullish on the potential success of E-1 (70% in our model), which may offer a favorable trading opportunity into the data." (6/13/2017)
• 5. According to Zacks Investment Research, "Seattle Genetics missed bottom-line expectations in the first quarter of 2017 but sales came in ahead of estimates. With the recent llabel expansion of Keytruda in the lymphoma indication, investor focus will likely remain on Adcetris sales in the upcoming quarters. A decline in Adcetris sales will hurt the company's top line. Though, the company has a number of candidates in its pipeline, most of them are in early stages of development. Although the clinical hold on several early-stage trials of vadastuximab talirine in acute myeloid leukemia (AML) was lifted in Mar 2017, Seattle Genetics has a long way to go before the candidate comes close to commercialization. However, the company’s collaboration agreement with Takeda for the global development and commercialization of Adcetris is encouraging. Also, collaborations with companies like AbbVie, Bayer, Roche and Pfizer provide it with funds in the form of upfront, milestone and other payments." (5/2/2017)

Some companies that are related to Seattle Genetics include Alnylam Pharmaceuticals (ALNY), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), INC Research Holdings (INCR), Galapagos NV (GLPG), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR) and WuXi PharmaTech (Cayman) (WX).

Seattle Genetics' management team includes the folowing people:

• Clay B. Siegall Ph.D., Chairman of the Board, President, Chief Executive Officer
• Todd E. Simpson, Chief Financial Officer
• Eric L. Dobmeier, Chief Operating Officer
• Jean I. Liu J.D., Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
• Darren S. Cline, Executive Vice President - Commercial
• Jonathan G. Drachman M.D., Chief Medical Officer, Executive Vice President - Research and Development
• Vaughn B. Himes Ph.D., Chief Technical Officer
• Felix J. Baker Ph.D., Lead Independent Director
• Srinivas Akkaraju M.D. Ph.D., Independent Director
• David W. Gryska, Independent Director

Seattle Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (11.07%), FMR LLC (5.50%), Vanguard Group Inc. (5.27%), BlackRock Inc. (5.21%), State Street Corp (1.96%) and Capital International Investors (1.90%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Wasatch Advisors Inc., Baillie Gifford & Co., Capital Guardian Trust Co., Gotham Asset Management LLC, Wells Fargo & Company MN and KBC Group NV. Company insiders that have sold Seattle Genetics stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Seattle Genetics' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Capital International Investors, Marshall Wace North America L.P., Matrix Capital Management Company LP, TIAA CREF Investment Management LLC, First Trust Advisors LP, Pictet Asset Management Ltd. and Tekla Capital Management LLC. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin. View Insider Buying and Selling for Seattle Genetics.

Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Seattle Genetics stock can currently be purchased for approximately $52.98.